Stock chart
Analyses on Purple Biotech (4)
- March 19, 2026March 19, 2026
- Follow-up
Purple Biotech: Does The Cash Really Get IM1240 Into The Clinic?
Purple’s current cash position looks sufficient to get IM1240 through GLP tox, an IND filing, and Phase 1 initiation, but it is a narrow bridge rather than a comfortable runway for the clinical stage beyond that point.
- Follow-up
Purple Biotech: What The CM24 And NT219 Write-Down Really Means
The 2025 CM24 and NT219 write-down is not a declaration that the programs have no clinical value. It is a reset of the balance-sheet value Purple Biotech was still willing to justify for them from an internally funded plan, leaving both programs as options that now need a partne…
- Follow-up
Purple Biotech: The Warrant Overhang, The ADS Ratio, And What It Does To The Financing Path
Purple Biotech's capital structure is no longer background noise. The warrant stack is larger than the current share base, it already sits as a liability on the balance sheet, and Nasdaq compliance now rests on another ADS ratio change. The financing path therefore depends not o…
Purple Biotech 2025: The Legacy Assets Were Written Down, The Cash Buys Time For IM1240
Purple Biotech is no longer a four-asset story. It is now a focused bet that IM1240 reaches the clinic on time while the legacy assets depend on partnership or outside funding.
